ZÜRICH, Switzerland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based T cell engager technology, today announced that preclinical data from the Company’s CDR101 candidate will be presented in a poster at the 63rd Annual American Society of Hematology (ASH) meeting being held in Atlanta, Georgia from December 11-14, 2021.
Details for the poster presentation are as follows:
Abstract Number: 1583
Poster Title: Preclinical Assessment of CDR101 – a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy
Session Number & Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I Hematology Disease Topics & Pathways: Biological, Translational Research, Bispecific Antibody Therapy, Plasma Cell Disorders, Checkpoint Inhibitor, Diseases, Therapies, Lymphoid Malignancies
Session Date: Saturday, December 11, 2021
Session Time: 5:30 PM – 7:30 PM
Presenter: Melissa Vrohlings, Immunology Expert, CDR-Life
About CDR-Life Inc.
CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Using a proprietary antibody platform that targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high potency and specificity, the company is advancing a portfolio of tumor-targeted T cell engagers for the treatment of high need solid tumor malignancies. CDR-Life is led by former biologics inventors, pharmaceutical drug developers and company builders, and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat geographic atrophy. For more information, please visit www.cdr-life.com.
Contacts:
Björn Peters, CBO
CDR-Life Inc.
Phone: +41 44 515 98 98
bjoern.peters@cdr-life.com
Argot Partners
CDR-Life@argotpartners.com
Phone: +1-212-600-1902
